ALVAC-HIV Placebo

BIOLOGICAL2 trials

Sponsors

U.S. Army Medical Research and Development Command

Conditions

HIV Infections

Phase 2

Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144

U.S. Army Medical Research and Development CommandHIV Infections

Start: 2012-04-30End: 2021-07-31Target: 162Updated: 2020-11-03

Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E

U.S. Army Medical Research and Development CommandHIV Infections

Start: 2013-09-24End: 2021-12-31Target: 360Updated: 2021-03-26

Related Papers

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability

AIDS2023-06-0113 citations

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response

PLoS Pathogens2023-05-317 citations

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.

2020-02-0638 citations

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

PLoS ONE2018-04-2717 citations

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

PLoS Pathogens2017-02-2448 citations

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

The Journal of Infectious Diseases2017-02-1770 citations

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa

PLoS ONE2014-11-179 citations